Σύγκριση μεθόδων
Εξετάστε τις επιλεγμένες μεθόδους δίπλα-δίπλα· οι γραμμές που διαφέρουν επισημαίνονται.
| Δείκτης Βλάβης Αγγειίτιδας (VDI)× | Δείκτης Δραστηριότητας Νόσου 28 Αρθρώσεων (DAS28)× | |
|---|---|---|
| Πεδίο | Ρευματολογία | Ρευματολογία |
| Οικογένεια | Process / pipeline | Process / pipeline |
| Έτος προέλευσης≠ | 2003 | 1995 |
| Δημιουργός≠ | Exley et al. | Prevoo et al. |
| Τύπος | Clinician-rated | Clinician-rated |
| Θεμελιώδης πηγή≠ | Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Pusey CD, Savage CO. Development and initial validation of the Vasculitis Damage Index (VDI) for systemic vasculitis. Arthritis & Rheumatism. 2003;48(7):2146-2157. link ↗ | Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48. DOI ↗ |
| Εναλλακτικές ονομασίες≠ | VDI, Vasculitis Permanent Organ Damage Score | DAS28, DAS28-CRP, DAS28-ESR |
| Συναφείς≠ | 4 | 3 |
| Σύνοψη≠ | The VDI is a clinician-assessed measure of permanent organ damage in patients with systemic vasculitis, including ANCA-associated vasculitis (AAV), polyarteritis nodosa, and other necrotising vasculitides. Introduced by Exley et al. (2003), VDI captures cumulative irreversible damage across organ systems, complementing disease activity measures (such as the Birmingham Vasculitis Activity Score). Systemic vasculitis is characterised by inflammation of blood vessel walls, leading to ischaemia and permanent tissue damage. VDI acknowledges that damage accrues over time and is largely irreversible, making it a prognostically important measure distinct from transient inflammatory activity. | The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden. |
| ScholarGateΣύνολο δεδομένων ↗ |
|
|